Clinical Trial

Methods of T Cell Depletion Trial (MoTD)

Name: Methods of T Cell Depletion Trial (MoTD) — clinical trial record (NCT04888741)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MoTD

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2021-05-10; most recent amendment 2026-04-29.

Trial Details

NCT Number	NCT04888741
Lead Sponsor	University of Birmingham Collaborators: The Jon Moulton Charity Trust, IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)
Conditions	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia +1 more
Enrollment	400 participants
Start Date	2021-02-22
Primary Completion	2027-08-23 (estimated)
Study Completion	2027-08-23 (estimated)
Updated on ClinicalTrials.gov	2026-05-05